Through the joint venture ADAMOS (ADAptive Manufacturing Open Solutions), DMG MORI, Dürr, Software AG and ZEISS as well as ASM PT are establishing a strategic alliance for the future topics of Industrie 4.0 and the Industrial Internet of Things (IIoT). Germany’s first alliance of well-known ... more
New Chairman of Supervisory Board at Carl Zeiss AGDr. Dieter Kurz elected with immediate effect
The Carl Zeiss AG Supervisory Board has elected Dr. Dieter Kurz as the new Chairman of the Supervisory Board, effective immediately.
Born in 1948, Dr. Dieter Kurz studied physics at the University of Tübingen, from which he also received his doctorate. He joined Carl Zeiss in 1979. After holding several responsible positions in research and development, marketing and sales, including a two-year stay in North America, he headed the Semiconductor Optics division and Semiconductor Manufacturing Technology busi- ness group. In 1999 he became a Member of the Executive Board and was appointed President and CEO in 2001. After the two Foundation enterprises had been transformed into stock corporations (AG) and the appropriate amendments to the Foundation's constitution had come into effect, he was President and CEO of Carl Zeiss AG from 2004 to the end of 2010.
Kurz is also Chairman of the Shareholder Council of the Carl Zeiss Foundation, Heidenheim and Jena, which is the sole shareholder of Carl Zeiss AG. He succeeds Dr. Theo Spettmann who held these offices from February 2010 and who stepped down for health reasons at the beginning of March 2012.
- Carl Zeiss
The Supervisory Board of Carl Zeiss AG has decided to continue the appointment of Dr. Michael Kaschke as President & CEO until 30 June 2020. Kaschke joined the ZEISS Group 25 years ago and has served on the Executive Board since 2000. He has been President & CEO of Carl Zeiss AG since 2011. ... more
The ZEISS Group had a very successful end to the first six months of fiscal year 2016/17 (ended 31 March) and saw its revenue rise by 10 percent to EUR 2.550 billion (1st half of 2015/16: EUR 2.322 billion). At EUR 384 million, the earnings before interest and tax (EBIT) were significantly ... more
- 1Mechanism involved in novel drug design with potential to treat tuberculosis
- 2Nanoscale virus features reconstructed from correlations of scattered X-rays
- 3New antibiotic resistance genes found
- 4Eurofins acquires food testing laboratory Institut Nehring
- 5Neutrons observe vitamin B6-dependent enzyme activity useful for drug development
- 6A detailed look at 2-D structure of turbulence in tokamaks
- 7Explaining how UV rays trigger skin cancer
- 8How rough microparticles can cause big problems
- 9Initiative taps scientists to create atlas of cells in human spinal cord
- 10Proteins may prevent dysfunction and disease by relaxing